Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Servier
Pharma
In a first, FDA approves Servier's Voranigo in low-grade gliomas
Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer.
Angus Liu
Aug 6, 2024 5:25pm
AstraZeneca climbs cancer reputation ranking to take 2nd spot
Jun 11, 2024 7:30am
New name takes top spot in US patient group reputation ranking
May 14, 2024 10:54am
Court reverses Servier verdict, orders payment of €430M
Dec 21, 2023 11:41am
Patients name US' most reputable pharma, ax Pfizer from top 3
May 10, 2023 8:40am
Takeda, Hutchmed hook up on cancer drug for $1.13B
Jan 23, 2023 10:31am